Combination of Lipitor and Celebrex inhibits prostate cancer VCaP cells in vitro and in vivo.

Huarong Huang, Xiao-Xing Cui, Shaohua Chen, Susan Goodin, Yue Liu, Yan He, Dongli Li, Hong Wang, Jeremiah Van Doren, Robert S Dipaola, Allan H Conney, Xi Zheng

Anticancer research 2014 Jul

filter terms:

Lipitor is a cholesterol-lowering drug and Celebrex is a Cyclooxygenase-2 inhibitor. We investigated the effects of Lipitor and Celebrex on human prostate cancer VCaP cells cultured in vitro and grown as orthotopic xenograft tumors in SCID mice. Apoptosis was measured by morphological assessment and caspase-3 assay. Nuclear factor-kappa B (NF-κB) activation was determined by luciferase reporter assay. B-cell lymphoma-2 (Bcl2) was measured by western blotting and immunohistochemistry. Orthotopic prostate tumors were monitored by the IVIS imaging system. the combination of Lipitor and Celebrex had stronger effects on the growth and apoptosis of VCaP cells than did either drug alone. The combination more potently inhibited activation of NFκB and expression of Bcl2 than either drug alone. The growth of orthotopic VCaP prostate tumors was strongly inhibited by treatment with the drug combination. Administration of Lipitor and Celebrex in combination may be an effective strategy for inhibiting the growth of prostate cancer. Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Citation

Huarong Huang, Xiao-Xing Cui, Shaohua Chen, Susan Goodin, Yue Liu, Yan He, Dongli Li, Hong Wang, Jeremiah Van Doren, Robert S Dipaola, Allan H Conney, Xi Zheng. Combination of Lipitor and Celebrex inhibits prostate cancer VCaP cells in vitro and in vivo. Anticancer research. 2014 Jul;34(7):3357-63